Although this treatment modality demonstrated efficacy in patient tumors expressing high TGF-β, there are currently no therapeutic strategies for HCC patients with a defective TGF-β pathway (low levels of TGF-β). The gene discussed is TGFB1; the disease is hepatocellular carcinoma.